SEC Form 10-K filed by Harvard Bioscience Inc.
$HBIO
Biotechnology: Laboratory Analytical Instruments
Industrials
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/9/2025 | Overweight → Sector Weight | KeyBanc Capital Markets | |
| 3/10/2023 | $3.00 → $4.00 | Speculative Buy → Buy | The Benchmark Company |
4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)
4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)
4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)
First Quarter 2026 Revenues of $20.8M and Gross Margin of 59%Consolidation of Manufacturing Operations Progressing on ScheduleReaffirms Full Year 2026 Financial Guidance HOLLISTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company" or "Harvard Bioscience") today announced financial results for the first quarter ended March 31, 2026. "First quarter revenues were in line with our expectations and gross margin expanded year-over-year, while we remained profitable on an adjusted EBITDA basis," said John Duke, President and Chief Executive Officer. "We are encouraged by the adoption rates of our NPI portfolio – specifically the MeshMEA™ organoid pla
HOLLISTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) today announced Chief Executive Officer, John Duke and Chief Financial Officer, Mark Frost's participation in the following upcoming investor events. Sidoti Micro Cap Conference Location: VirtualDate: Thursday, May 21, 2026Fireside Chat Presentation: 11:30 AM ET Benchmark (StoneX) Healthcare House Call Virtual Conference Location: VirtualDate: Thursday, May 28, 2026 A live webcast of the Sidoti fireside chat will be made available on Harvard Bioscience's Investor Relations website. An archived replay of the webcast will be available following the event. About Harvard Bioscience Harvard Bioscienc
HOLLISTON, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) will announce its financial results for the quarter ended March 31, 2026, before the market opens on May 12, 2026, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. Analysts who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here. Financial information presented on the call, including the earnings release and a related slide presentation, wil
8-K - HARVARD BIOSCIENCE INC (0001123494) (Filer)
SD - HARVARD BIOSCIENCE INC (0001123494) (Filer)
SCHEDULE 13G/A - HARVARD BIOSCIENCE INC (0001123494) (Subject)
4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)
4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)
4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)
KeyBanc Capital Markets downgraded Harvard Biosci from Overweight to Sector Weight
The Benchmark Company upgraded Harvard Biosci from Speculative Buy to Buy and set a new price target of $4.00 from $3.00 previously
KeyCorp reiterated coverage of Harvard Bioscience with a rating of and set a new price target of $9.00 from $6.00 previously
First Quarter 2026 Revenues of $20.8M and Gross Margin of 59%Consolidation of Manufacturing Operations Progressing on ScheduleReaffirms Full Year 2026 Financial Guidance HOLLISTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company" or "Harvard Bioscience") today announced financial results for the first quarter ended March 31, 2026. "First quarter revenues were in line with our expectations and gross margin expanded year-over-year, while we remained profitable on an adjusted EBITDA basis," said John Duke, President and Chief Executive Officer. "We are encouraged by the adoption rates of our NPI portfolio – specifically the MeshMEA™ organoid pla
HOLLISTON, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) will announce its financial results for the quarter ended March 31, 2026, before the market opens on May 12, 2026, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. Analysts who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here. Financial information presented on the call, including the earnings release and a related slide presentation, wil
Fourth Quarter 2025 Revenues of $23.7M and Gross Margin of 59.7%Full Year 2025 Revenues of $86.6M and Gross Margin of 57.7%Interim CFO Mark Frost Appointed CFO on Permanent BasisIntroduces Full Year 2026 Guidance which Reflects Anticipated Revenue Growth Driven by New Products for Translational Science HOLLISTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company" or "Harvard Bioscience") today announced financial results for the fourth quarter and full year ended December 31, 2025. "2025 was a pivotal year for Harvard Bioscience as we strengthened our balance sheet and streamlined our operating model. This culminated in fourth quarter results
Completes Repayment of Existing Credit Agreement, Extends Debt Maturity, and Enhances Financial FlexibilityBroadOak Partner Bill Snider to Join Board of Directors and Company to Form Advisory Board on Growth and Operating Opportunities HOLLISTON, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company" or "Harvard Bioscience"), today announced it entered into an agreement with BroadOak Capital Partners (collectively, "BroadOak"), a life-sciences-focused investment and advisory firm, to provide a $40 million credit facility comprised of three term loans, all of which will be funded on December 17, 2025. The proceeds of the facility will be used to ret
HOLLISTON, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company" or "Harvard Bioscience") today announced the appointment of Stephen DeNelsky to its Board of Directors, effective September 5, 2025. Mr. DeNelsky will also serve on the Board's Nominating and Governance Committee. "We are pleased to announce Steve as the newest member of our Board of Directors at such an important time for Harvard Bioscience," said John Duke, President & CEO. "His knowledge across the verticals we operate in, as well as his expertise in guiding life sciences companies on financial strategy will be invaluable as we move forward." "I'm honored to join the Board and lo
Current Board member John Duke to succeed Jim Green as President & CEO Rob Gagnon and Seth Benson appointed as new Board membersQ2 '25 revenue anticipated to be $20.4 million and Company reiterates previously announced Q2 ‘25 gross margin guidance HOLLISTON, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company" or "Harvard Bioscience") today announced a CEO succession plan under which John Duke will assume the role of President & CEO following the planned retirement of Jim Green, effective July 28, 2025. Jim Green will be retiring from his President, CEO & Chairman roles at Harvard Bioscience after more than 8 years as Chairman and 6 years as Pre
SC 13G/A - HARVARD BIOSCIENCE INC (0001123494) (Subject)
SC 13G - HARVARD BIOSCIENCE INC (0001123494) (Subject)
SC 13G/A - HARVARD BIOSCIENCE INC (0001123494) (Subject)